Premarket Summary:
CTIC: Our best pick of 2014
http://stocktwits.com/message/19163866
AMRN Amarin announces FDA DMEP 'does not plan to reinstate ANCHOR SPA agreement'.
PSTI Pluristem muscle injury trial meets primary safety, efficacy endpoints.
GPS Gap upgraded to Buy from Underperform at Sterne Agee YGE Yingli Green obtains certificate for contracting foreign projects from PRC.
NQ Altimeter reports NQ Mobile stake of 9.9% with rights to acquire 7.4% more.
ENDP, PATH Endo Health announces NuPathe terminated merger agreement.
BCRX BioCryst initiated with a Buy at Roth Capital Target $18.
VVUS, AUXL VIVUS and Auxilium announces FDA accepted STENDRA's supplemental application PDUFA date is September 20, 2014.
SRPT Needham upgraded Sarepta due to valuation and continued positive data from the eteplirsen Phase IIb trial. Price target is $36.
ADXS Advaxis announces first patient dosed in Phase 1/2 ADXS-HPV GALT Preclinical study shows effect of Galectin GR-MD-02 on serum biomarker on NASH.
BLRX BioLineRx receives approval to commence pivotal trial for novel skin lesion treatment
GALT Preclinical study shows effect of Galectin GR-MD-02 on serum biomarker on NASH
Other Active Stock to watch:
ICPT, NLST, CHTP, JRCC, RTRX
For Further reading join our Premium services http://www.freefdawatchlist.com/p/our-services.html
CTIC: Our best pick of 2014
http://stocktwits.com/message/19163866
AMRN Amarin announces FDA DMEP 'does not plan to reinstate ANCHOR SPA agreement'.
PSTI Pluristem muscle injury trial meets primary safety, efficacy endpoints.
GPS Gap upgraded to Buy from Underperform at Sterne Agee YGE Yingli Green obtains certificate for contracting foreign projects from PRC.
NQ Altimeter reports NQ Mobile stake of 9.9% with rights to acquire 7.4% more.
ENDP, PATH Endo Health announces NuPathe terminated merger agreement.
BCRX BioCryst initiated with a Buy at Roth Capital Target $18.
VVUS, AUXL VIVUS and Auxilium announces FDA accepted STENDRA's supplemental application PDUFA date is September 20, 2014.
SRPT Needham upgraded Sarepta due to valuation and continued positive data from the eteplirsen Phase IIb trial. Price target is $36.
ADXS Advaxis announces first patient dosed in Phase 1/2 ADXS-HPV GALT Preclinical study shows effect of Galectin GR-MD-02 on serum biomarker on NASH.
BLRX BioLineRx receives approval to commence pivotal trial for novel skin lesion treatment
GALT Preclinical study shows effect of Galectin GR-MD-02 on serum biomarker on NASH
Other Active Stock to watch:
ICPT, NLST, CHTP, JRCC, RTRX
For Further reading join our Premium services http://www.freefdawatchlist.com/p/our-services.html
No comments:
Post a Comment